In our view, transient treatment with ICAM-1 blocking antibodies together with immunotherapy would release cytotoxic T lymphocytes caught up in clusters, setting them free to kill tumor cells or egress to the dLNs and to subsequent lesions. The gene discussed is ICAM1; the disease is neoplasm.